

# **Technical Data**

# **HiCrome Acinetobacter Agar Base**

M1938

For selective isolation of *Acinetobacter* species from environmental and clinical samples.

### Composition\*\*

Ingredients	Gms / Litre
Peptone special	9.000
Sodium chloride	5.000
Selective mix	0.500
Chromogenic mixture	1.350
Agar	15.000
Final pH ( at 25°C)	7.0±0.2

<sup>\*\*</sup>Formula adjusted, standardized to suit performance parameters

#### **Directions**

Suspend 30.85 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely. DO NOT AUTOCLAVE. Cool to 45-50°C and add the rehydrated contents of two vials of MDR Selective Supplement (FD271). Mix well and pour into sterile Petri plates.

#### **Principle And Interpretation**

Acinetobacter species are gram negative bacteria ubiquitous bacteria that have been isolated from patients with nosocomial infection, environment, soil, and water. Acinetobacter is mostly found in every type of infections (3). There is an alarming situation as Acinetobacter baumannii is found to be resistant to most commonly used antibiotics which includes beta-lactams and aminoglycosides (2,3). Immunocompromised patients requiring mechanical respirations are at more risk of infection by Acinetobacter species.(1)

Peptone special provides nitrogeneous compounds and vitamins to the organisms. Sodium chloride maintains the osmotic balance. Selective mix inhibits gram positive organisms. The chromogenic mixture in the medium allows the differentiation of *Acinetobacter* species from other organisms.

### **Quality Control**

# Appearance

Light yellow to yellow homogeneous free flowing powder

#### Gelling

Firm, comparable with 1.5% Agar gel

#### Colour and Clarity of prepared medium

Yellow coloured clear to slightly opalescent gel forms in petriplate.

#### Reaction

Reaction of 3.09% w/v aqueous solution at 25°C. pH: 7.0±0.2

# pН

6.8-7.2

#### **Cultural Response**

Cultural characteristics observed after an incubation at 35-37°C for 24-48 hours.

Organism	Inoculum (CFU)	Growth	Observed Lot value (CFU) with FD271	Recovery with TFD271	Colour of colony
Cultural Response Acinetobacter baumannii ATCC BAA-1605	50 -100	luxuriant	25 -100	>=50 %	Light purple with halo
Acinetobacter baumannii ATCC BAA-747	>=103	inhibited	0	0 %	-

HiMedia Laboratories Technical Data

Acinetobacter baumannii ATCC 19606	>=103	inhibited	0	0 %	-
Acinetobacter lwofii ATCC 15309	>=103	inhibited	0	0 %	-
Acinetobacter haemolyticus ATCC 19002	>=103	inhibited	0	0 %	-
Escherichia coli ATCC 25922	>=103	inhibited	0	0 %	-
Enterococcus faecalis ATCC 29212	>=103	inhibited	0	0 %	-

#### Storage and Shelf Life

Store dehydrated powder and prepared medium at 2-8°C in tightly closed container. Use before expiry period on the label.

#### Reference

- 1.Bergogne- Berezin, E., m. L. Joly-Guillou, and J.F. Vieu. 1987. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus . J. Hosp. Infect. 10:105-113
- 2.Montefour, K., et.al.2008. Acinetobacter baumanni : An EmergingMultidrug Resistant pathogen in critical care Nurse; 28:15-25
- 3. Valentine, S.C., et.al. 2008 Phenotypic and molecular characterization of Acinetobacter baumanni. Clinical isolates from nosocomial outbreaks in Los Angeles Country, California. J.Clin. Microbiology.; 46:2499-2507

Revision: 1/2011

# (€

#### Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMedia<sup>™</sup> publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMedia<sup>™</sup> Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.